Clinical outcomes and safety of combined calcitriol and bisphosphonates in treating postmenopausal osteoporosis: a retrospective cohort study
Abstract Objective Despite the well-known benefits of calcitriol and bisphosphonates in managing osteoporosis, limited research has explored the combined therapeutic effects of these agents on bone metabolism, immune function, and clinical outcomes in postmenopausal osteoporosis patients. This study...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Orthopaedic Surgery and Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13018-025-05714-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Objective Despite the well-known benefits of calcitriol and bisphosphonates in managing osteoporosis, limited research has explored the combined therapeutic effects of these agents on bone metabolism, immune function, and clinical outcomes in postmenopausal osteoporosis patients. This study aims to evaluate the clinical efficacy and safety of calcitriol combined with bisphosphonates in the treatment of postmenopausal osteoporosis through a retrospective cohort analysis. Methods A total of 152 postmenopausal osteoporosis patients treated at our hospital from March 2019 to June 2021 were enrolled and divided into two groups based on the treatment received. The control group received calcitriol alone, while the study group received calcitriol combined with bisphosphonates. Treatment outcomes were assessed by comparing Visual Analogue Scale (VAS) scores for pain, Barthel Index for daily living ability, and Oswestry Disability Index (ODI) for dysfunction before and after treatment. Bone metabolism markers (BALP, BGP, PINP, TRACP), immune cytokines (IL-6, TGF-β1, TNF-α, IL-10), and bone mineral density (BMD) were measured. The incidence of adverse reactions was also recorded. Results The total effective rate in the study group was 96.05%, significantly higher than 84.21% in the control group (P < 0.05). Post-treatment VAS and ODI scores decreased significantly in both groups, with greater improvement in the study group (P < 0.05). Barthel Index scores increased more in the study group (P < 0.05). Bone metabolism markers (BALP, BGP, PINP, TRACP) and inflammatory cytokines (IL-6, TGF-β1, TNF-α) decreased more significantly in the study group, while IL-10 levels and BMD increased more markedly (P < 0.05). The incidence of adverse reactions was lower in the study group (2.63%) than in the control group (5.26%), but the difference was not statistically significant (P > 0.05). Conclusion The combination of calcitriol and bisphosphonates demonstrates superior clinical efficacy and safety in treating postmenopausal osteoporosis, effectively reducing pain and disability, enhancing bone metabolism and immune function, and improving bone mineral density and daily living ability. |
|---|---|
| ISSN: | 1749-799X |